This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Zhang N, Wu J, Wang Q et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023; 13(1): 82.ZhangNWuJWangQ.Global burden of hematologic malignancies and evolution patterns over the past 30 years..2023;13(1):82.Search in Google Scholar
Rao D, Said J. Pathology and Molecular Pathology of Hematologic MalignanciesRaoDSaidJ.Search in Google Scholar
Beck RC, Kim AS, Goswami RS et al. A Recommended Curriculum From The Society for Hematopathology and the Association for Molecular Pathology. Am J Clin Pathol 2020;154:149–177BeckRCKimASGoswamiRS.A Recommended Curriculum From The Society for Hematopathology and the Association for Molecular Pathology.2020;154:149–177Search in Google Scholar
Mukkamalla SKR, Taneja A, Malipeddi D et al. Chronic Lymphocytic Leukemia. StatPearls Publishing; 2024 Jan-.MukkamallaSKRTanejaAMalipeddiD..StatPearls Publishing;2024Jan-.Search in Google Scholar
Wainman LM, Khan WA, Kaur P. Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing. In: Sergi CM, editor. Advancements in Cancer Research. Brisbane (AU): Exon Publications; Online first 08 Feb 2023. p. 93–106WainmanLMKhanWAKaurP.Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing. In:SergiCM, editor..Brisbane (AU):Exon Publications; Online first 08 Feb 2023. p.93–106Search in Google Scholar
Goy J, Gillan TL, Bruyere H et al. Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada. Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 6, 2017, p. 382–389.GoyJGillanTLBruyereH.Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada., Volume17, Issue6,2017, p.382–389.Search in Google Scholar
Dave SS, Fu K, Wright GW et al. Molecular Diagnosis of Burkitt’s Lymphoma. N Engl J Med 2006; 354:2431–2442DaveSSFuKWrightGW.Molecular Diagnosis of Burkitt’s Lymphoma.2006;354:2431–2442Search in Google Scholar
Burkhardt, B, Michgehl, U, Rohde, J. et al. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun 13, 3881 (2022).BurkhardtBMichgehlURohdeJ..Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.13,3881(2022).Search in Google Scholar
Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer J. 2020 May/Jun;26(3):195–205.RoschewskiMPhelanJDWilsonWH.Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma..2020May/Jun;26(3):195–205.Search in Google Scholar
Navarro A, Beà S, Jares P et al. Molecular Pathogenesis of Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020 Oct;34(5):795–807NavarroABeàSJaresP.Molecular Pathogenesis of Mantle Cell Lymphoma..2020Oct;34(5):795–807Search in Google Scholar
Jain P, Wang ML. Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach,and current and novel treatments. Am J Hematol.2022;97:638–656.JainPWangML.Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach,and current and novel treatments..2022;97:638–656.Search in Google Scholar
López C, Mozas P, López-Guillermo A et al. Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice. Hemato 2022, 3(4), 595–614.LópezCMozasPLópez-GuillermoA.Molecular Pathogenesis of Follicular Lymphoma: From Genetics to Clinical Practice.2022,3(4),595–614.Search in Google Scholar
Bohn JP, Salcher S, Pircher A et al. The Biology of Classic Hairy Cell Leukemia. Int. J. Mol. Sci. 2021, 22(15), 7780BohnJPSalcherSPircherA.The Biology of Classic Hairy Cell Leukemia..2021,22(15),7780Search in Google Scholar
Durham BH, Getta B, Dietrich S et al. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Oct 5; 130(14): 1644–1648.DurhamBHGettaBDietrichS.Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations..2017Oct5;130(14):1644–1648.Search in Google Scholar
Rodríguez-Sevilla JJ, Salar A. Recent Advances in the Genetic of MALT Lymphomas. Cancers 2022, 14(1), 176Rodríguez-SevillaJJSalarA.Recent Advances in the Genetic of MALT Lymphomas.2022,14(1),176Search in Google Scholar
Heider M, Nickel K, Högner M et al. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncol Res Treat (2021) 44 (12): 672–681.HeiderMNickelKHögnerM.Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.(2021)44(12):672–681.Search in Google Scholar
Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 2021, 10(2), 336Cardona-BenavidesIJde RamónCGutiérrezNC.Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.2021,10(2),336Search in Google Scholar
Foucar K, Bagg A, Bueso-Ramos CE et al. Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach, American Journal of Clinical Pathology, Volume 160, Issue 4, October 2023, Pages 365–393.FoucarKBaggABueso-RamosCE.Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach,, Volume160, Issue4,October2023, Pages365–393.Search in Google Scholar
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood (2017) 129 (6): 667–679.VainchenkerWKralovicsR.Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.(2017)129(6):667–679.Search in Google Scholar
Alshemmari SH, Rajan R, Emadi A. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review. Med Princ Pract (2016) 25 (6): 501–509.AlshemmariSHRajanREmadiA.Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.(2016)25(6):501–509.Search in Google Scholar
Sara Benchikh S, Bousfiha A, Hamouchi AE et al. Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution. Egypt J Med Hum Genet 23, 29 (2022).Sara BenchikhSBousfihaAHamouchiAE.Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution.23,29(2022).Search in Google Scholar
Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica 2017 Volume 102(1):7–17.GrinfeldJNangaliaJGreenAR.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.2017Volume102(1):7–17.Search in Google Scholar
Prins D,1 Arias CG,1 Klampfl T. Mutant Calreticulin in the Myeloproliferative Neoplasms. Hemasphere. 2020 Feb; 4(1): e333.PrinsD1AriasCG1KlampflT.Mutant Calreticulin in the Myeloproliferative Neoplasms..2020Feb;4(1): e333.Search in Google Scholar
Haferlach T. The Molecular Pathology of Myelodysplastic Syndrome. Pathobiology (2019) 86 (1): 24–29.HaferlachT.The Molecular Pathology of Myelodysplastic Syndrome.(2019)86(1):24–29.Search in Google Scholar
Lee P, Yim R, Yung Y, Chu H-T, Yip P-K, Gill H. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome. International Journal of Molecular Sciences. 2021; 22(19):10232.LeePYimRYungYChuH-TYipP-KGillH.Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome..2021;22(19):10232.Search in Google Scholar
Demir D. Insights into the new molecular updates in acute myeloid leukemia pathogenesis. Genes 2023,14,1424.DemirD.Insights into the new molecular updates in acute myeloid leukemia pathogenesis.2023,14,1424.Search in Google Scholar
Khoury JD, Solary E, Abla O et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7): 1703–1719.KhouryJDSolaryEAblaO.The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms..2022;36(7):1703–1719.Search in Google Scholar
Döhner H, Wei AH, Appelbaum FR et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140: 1345–1377.DöhnerHWeiAHAppelbaumFR.Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN..2022;140:1345–1377.Search in Google Scholar
Graham BS, Lynch DT. Burkitt Lymphoma. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538148/GrahamBSLynchDT.Burkitt Lymphoma. [Updated 2023 Aug 7]. In:[Internet].Treasure Island (FL):StatPearls Publishing;2024Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK538148/Search in Google Scholar
Kim S, Kim H, Kang H et al. Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. J Hematol Oncol. 2013 Oct 3;6:76.KimSKimHKangH.Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement..2013Oct3;6:76.Search in Google Scholar
Sehn LH, Fenske TS, Laport GG. Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 18:S82–S91, 2012SehnLHFenskeTSLaportGG.Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation.18:S82–S91,2012Search in Google Scholar